Date: 2014-03-27
Type of information: R&D agreement
Compound: antibodies
Company: Genmab (Denmark) MAB Discovery (Germany)
Therapeutic area: Technology - Services
Type agreement: R&D
Action mechanism:
Disease:
Details: * On March 27, 2014, MAB Discovery GmbH, a privately held biotechnology company focused on the generation of antibody therapeutics, has announced it has entered into a collaboration with Genmab and its affiliate Genmab BV. Under the terms of the agreement, MAB Discovery will generate antibodies for multiple Genmab targets in support of their development of therapeutic antibody products. MAB Discovery will employ its in vivo antibody discovery technology platform, which relies on the natural immune response of rabbits followed by state of the art B-cell cloning techniques. Using a novel high-throughput screening route, MAB Discovery focuses on identifying highly active antibodies with unprecedented epitope coverage, potency and species-cross-reactivity which has been successful for intractable targets. This technology eliminates affinity maturation and surrogate development which is very time consuming. The deal terms are not disclosed.
Financial terms:
Latest news:
